Abstract Library

#2149 Symptomatic Hypothalamic-Pituitary Metastases Disclosing Malignant Paraganglioma

Introduction: A paraganglioma is a rare tumor composed of chromaffin cells. Malignant paraganglioma is a very rare presentation diagnosed by local recurrence after total resection of the primary mass or findings of distant metastasis. We report a case of a 34-year-old women with a Malignant paraganglioma presneting with visual loss and hypopituitarism resulting from metastasis to the pituitary area. The diagnosis of malignant paraganglioma was based on loco-regional and distant metastasis

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Bengueddach A, kehili h, Yamouni M, Boudjnane n, tabeti b,

Keywords: Paraganglioma, Brain Metastasis,

#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures

Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Romano D

Authors: Mohamed A, Romano D, Poizat F, Delpero J, Niccoli P,

Keywords: pNETs primary culture, everolimus, somatostatin analogues, cell viability, chromogranin A secretion, Akt activity,

#1300 Staging of Neuroendocrine Tumors: Value of Hybrid Imaging With 111In- Pentetreotide

Introduction: Neuroendocrine tumors (NET) are rare and can occur anywhere in the body. Ninety-eight percent of these tumors express the type 2 of somatostatin receptors, making possible the functional imaging of NET. 111In-labelled pentetreotide specifically binds to somatostatin receptors, with particular affinity to subtypes 2 and 5.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Khamla E

Authors: Ben Sellem D, Khamla E, Ben Slimene M,

Keywords: Neuroendocrine tumor,

#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma

Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Khamla E

Authors: Khamla E, Ben Sellem D, Ben Slimene M,

Keywords: Medullary Thyroid Carcinoma, Somatostatin Receptor Scintigraphy, Management ,

#1140 Incremental Benefit of Preoperative Endoscopic Ultrasound for the Detection of Pancreatic Neuroendocrine Tumors: A Meta-Analysis

Introduction: Current guidelines recommend computed tomography (CT) scan or magnetic resonance imaging as the initial imaging modalities for the work-up of suspected pancreatic neuroendocrine tumors (PNETs).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tsolakis A

Authors: Tsolakis A, James P, Zhang M, Belletrutti P, Mohamed R,

Keywords: Pancreatic neuroendocrine tumor, Radiological investigation, Incremental benefit, Endoscopic Ultrasound,